Article

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors

2024-03-25

Abstract excerpt

Neurofibromatosis Type 1 (NF1) is a common cancer predisposition syndrome, caused by heterozygous loss of function mutations in the tumor suppressor gene NF1 . Individuals with NF1 develop benign tumors of the peripheral nervous system (neurofibromas), originating from the Schwann cell linage after somatic loss of the wild type NF1 allele, some of which progress further to malignant peripheral nerve sheath tumor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f80fa600-49ec-55df-a661-34fc03f711bc
DOI: 10.1101/2024.03.25.585959

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumorsDOI 10.1101/2024.03.25.585959Read

Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and PotencySemantic proximity Read

New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.Semantic proximity Read

A novel combinatorial treatment for Neurofibromatosis type 1 tumours revealed through cross-species genetic analysisSemantic proximity Read

Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistanceSemantic proximity Read

A novel combinatorial treatment for Neurofibromatosis type 1 tumours revealed through cross-species genetic analysisSemantic proximity Read

Prioritizing Combinational Drug Screening: A Ranking System for <i>In Vitro</i> Drug Combinations in Neurofibromatosis Type 1Semantic proximity Read

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2Semantic proximity Read

NF1 alterations in cancers: therapeutic implications in precision medicineSemantic proximity Read

Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaSemantic proximity Read

Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors.Semantic proximity Read

Inhibition of autophagy as a novel therapy for the treatment of neurofibromatosis type 1 tumorsSemantic proximity Read

Functional interactions between neurofibromatosis tumor suppressors drive Schwann cell tumor de-differentiation and treatment resistanceSemantic proximity Read